ProfileJobs

Capricor Therapeutics

Healthbiotechclinicshealthtechplatform
Capricor Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics for the treatment of diseases. Its lead programs target post myocardial infarction (heart attack), heart failure and Duchenne Muscular Dystrophy. As a developer of innovative therapies, Capricor Therapeutics is strategically positioned at the forefront of one of the largest segments of the U.S. healthcare industry − cardiovascular disease.
Revenue(Q1, 2017)
$880.8 K
Market capitalization(2017-08-15)
$23.5 M
Company Growth (employees)
Type
Public
HQ
Beverly Hills, US
Founded
2005
Size (employees)
29 (est)
Website
capricor.com
Capricor Therapeutics was founded in 2005 and is headquartered in Beverly Hills, US

Capricor Therapeutics Office Locations

Capricor Therapeutics has an office in Beverly Hills
Beverly Hills, US (HQ)
8840 Wilshire Blvd

Capricor Therapeutics Data and Metrics

Capricor Therapeutics Financial Metrics

Capricor Therapeutics's revenue was reported to be $880.8 k in Q1, 2017
USD

Revenue (Q1, 2017)

880.8 k

Net income (Q1, 2017)

(3.7 m)

EBIT (Q1, 2017)

(3.6 m)

Market capitalization (15-Aug-2017)

23.5 m

Cash (31-Mar-2017)

2.8 m
Capricor Therapeutics's current market capitalization is $23.5 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

503.2 k4.8 m5.5 m4 m

Revenue growth, %

851%15%(28%)

R&D expense

5.2 m

General and administrative expense

2.2 m

Operating expense total

7.4 m10.8 m18.1 m21 m

EBIT

(6.9 m)(6 m)(12.6 m)(17 m)

EBIT margin, %

(1372%)(126%)(229%)(425%)

Interest expense

58.1 k200.5 k248.6 k344.7 k

Net Income

(8.9 m)(6.2 m)(12.9 m)(18.8 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

1 m1.3 m1.8 m1.3 m1.3 m1.2 m1.1 m746.8 k880.8 k

R&D expense

1.9 m2 m3.8 m3.4 m3.2 m4.3 m4.3 m4.7 m3.3 m

General and administrative expense

665.7 k819.7 k1.4 m926.3 k972.8 k1.1 m1.4 m1.3 m1.2 m

Operating expense total

2.5 m2.8 m5.2 m4.4 m4.2 m5.4 m5.7 m6 m4.4 m

EBIT

(1.5 m)(1.5 m)(3.4 m)(3.1 m)(2.9 m)(4.2 m)(4.6 m)(5.2 m)(3.6 m)

EBIT margin, %

(142%)(114%)(191%)(237%)(217%)(347%)(408%)(702%)(405%)

Interest expense

(54.7 k)(60.1 k)(61.7 k)(61.7 k)(61.7 k)(66.1 k)(76.9 k)(98.7 k)(105.3 k)

Net Income

(1.5 m)(1.5 m)(3.5 m)(3.1 m)(2.9 m)(4.3 m)(4.7 m)(5.3 m)(3.7 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

1.7 m8 m5.6 m3.2 m

Accounts Receivable

187

Inventories

222.8 k235.5 k210.6 k342.9 k

Current Assets

3.7 m11.6 m14 m18.1 m

PP&E

229.5 k318.6 k435.3 k

Total Assets

5.5 m13.6 m16.1 m18.7 m

Accounts Payable

1.5 m1.7 m2.5 m3 m

Current Liabilities

2.1 m6.3 m6.5 m4.9 m

Non-Current Liabilities

4 m13.6 m10.6 m17.9 m

Total Liabilities

6.1 m19.9 m17.1 m22.8 m

Additional Paid-in Capital

15.6 m16.1 m34.1 m50 m

Retained Earnings

(22.3 m)(35.2 m)(54 m)

Total Equity

(534.9 k)(6.2 m)(1 m)(4 m)

Financial Leverage

-10.4 x-2.2 x-15.6 x-4.7 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

11.6 m9.8 m6.9 m5 m4.2 m11.8 m8.9 m18 m2.8 m

Accounts Receivable

230823

Current Assets

16.4 m14.2 m25.4 m21.6 m17.7 m14.9 m11.8 m22.4 m13.5 m

PP&E

253.8 k263.1 k332.1 k345 k355.3 k351.5 k411.9 k

Total Assets

18.4 m16.3 m27.5 m23.7 m19.9 m17 m13.9 m24.5 m14.1 m

Accounts Payable

55.3 k55.3 k2.7 m2.7 m2.3 m3.2 m2.9 m3.9 m2.5 m

Current Liabilities

6.5 m6.2 m7.5 m6.9 m6.5 m7.3 m6.2 m6.7 m3.3 m

Non-Current Liabilities

15 m14.6 m12.6 m12.3 m11.4 m10.7 m12.8 m17.8 m18 m

Additional Paid-in Capital

15.7 m15.9 m33.1 m33.4 m33.7 m38.3 m39 m49.5 m50.4 m

Retained Earnings

(25.8 m)(28.9 m)(31.8 m)(39.4 m)(44.1 m)(49.5 m)(57.6 m)

Total Equity

(3.1 m)(4.5 m)7.3 m4.6 m1.9 m(1.1 m)(5.1 m)49.1 k(7.2 m)

Financial Leverage

-6 x-3.6 x3.8 x5.2 x10.3 x-15.7 x-2.7 x498.1 x-2 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(8.9 m)(6.2 m)(12.9 m)(18.8 m)

Depreciation and Amortization

26.9 k41.9 k110.9 k125.7 k

Accounts Receivable

25 k

Inventories

(161.6 k)(12.6 k)24.9 k(132.3 k)

Accounts Payable

974.7 k70.3 k831.2 k508.3 k

Cash From Operating Activities

(6.1 m)958.6 k(10.8 m)(15.8 m)

Purchases of PP&E

(186.4 k)(129.7 k)(192 k)

Cash From Investing Activities

3.8 m141 k(8.1 m)(5.2 m)

Cash From Financing Activities

3.9 m5.2 m16.5 m18.6 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(1.5 m)(1.5 m)(3.5 m)(3.1 m)(2.9 m)(4.3 m)(4.7 m)(5.3 m)(3.7 m)

Accounts Receivable

230823

Accounts Payable

1.7 m1.6 m2.7 m2.7 m2.3 m3.2 m2.9 m3.9 m2.5 m
USDY, 2017

Revenue/Employee

30.4 k

Financial Leverage

-2 x

Capricor Therapeutics Market Value History

Market Position of Capricor Therapeutics

Competitors

Adaptive Biotechnologies
Health - Private
Advaxis
Health - Public
Immunocore
Health - Private
OptiScan Biomedical
Health - Private
Compare competitors

Traffic Overview of Capricor Therapeutics

Capricor Therapeutics Online and Social Media Presence

Capricor Therapeutics Company Life and Culture

You may also be interested in